SCHEMBL1361020

SCHEMBL1361020

COC(C)OCOc1cc2ccc(-c3ccc(C(=O)O)cc3)cc2cc1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
THRB P10828 1/20 0.58
RECQL P46063 1/20 0.58
NR2E1 Q9Y466 1/20 0.58
RARB P10826 10/20 0.58
RARG P13631 10/20 0.58
RARA P10276 10/20 0.58
NR1I2 O75469 1/20 0.58
LMNA P02545 1/20 0.58
PGR P06401 1/20 0.58
HSPD1 P10809 1/20 0.58
GOT1 P17174 1/20 0.58
GLRA1 P23415 1/20 0.58
BLM P54132 1/20 0.58
HSPE1 P61604 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7929420 0.99 MEN1 (0.57) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL7929371 0.93 RARB (0.51) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL7927672 0.92 RARB (0.50) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL7929425 0.92 RARB (0.50) MEN1KMT2ATHRBRECQLNR2E1
Acetic Acid SCHEMBL7926656 0.90 RARB (0.48) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL6032184 0.90 RARG (0.53) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL7926526 0.89 RARB (0.46) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL7929996 0.89 RARB (0.47) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL7926557 0.89 RARB (0.45) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL1684004 0.89 RARB (0.48) MEN1KMT2ATHRBRECQLNR2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8066976-B2 Foaming compositions for hair care GALDERMA S.A. (CH) 2011-11-29 US claimed
US-20100234337-A1 FOAMING COMPOSITIONS FOR HAIR CARE GALDERMA S.A. (CH) 2010-09-16 US claimed
US-20100144683-A1 METHODS FOR GENERATING MAMMALIAN MODELS OF ATOPIC DISEASES, AND SCREENING FOR THEIR TREATMENT ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI) (FR) 2010-06-10 US claimed
EP-2046309-A2 USE OF VITAMIN D3 AGONIST IN A MAMMALIAN MODEL FOR ATOPIC DISEASES AND OF VITAMIN D3 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DISEASES Association pour la recherche à l'IGBMC (ARI) (FR) 2009-04-15 EP claimed
EP-1891944-A1 Use of Vitamin D3 agonist in a mammalian model for atopic diseases and of Vitamin D3 antagonists for the treatment of atopic diseases Association pour la recherche à l'IGBMC (ARI) (FR) 2008-02-27 EP claimed
WO-2008012645-A2 USE OF VITAMIN D3 AGONIST IN A MAMMALIAN MODEL FOR ATOPIC DISEASES AND OF VITAMIN D3 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DISEASES ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI) (FR) 2008-01-31 WO claimed
EP-1087747-B1 FOAMING COMPOSITION FOR HAIR CARE GALDERMA SA (CH) 2005-11-09 EP claimed
EP-0874626-B1 USE OF INHIBITORS OF RETINOIC ACID ACTIVITY FOR WOUND HEALING CT INTERNAT DERECH S DERMATOLO (FR) 2004-12-29 EP claimed
EP-0892633-B1 USE OF INHIBITORS OF THE ACTIVITY OF RETINOIC ACID FOR TREATING SENSITIVE SKIN AND/OR ACUTE DAMAGE INDUCED BY UV RADIATION GALDERMA RECH DERMATOLOGIQUE (FR) 2003-03-05 EP claimed
EP-0854711-B1 gamma-RAR ANTAGONIST LIGAND OR alpha-RAR AGONIST LIGAND AS AN APOPTOSIS INHIBITOR GALDERMA RECH DERMATOLOGIQUE (FR) 2002-01-23 EP claimed
US-6248749-B1 TOPICALLY APPLYING RETINOID ANTAGONIST TO SENSITIVE SKIN TO TREAT ALLERGIES/SUNBURN CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 2001-06-19 US claimed
US-6063797-A γ-RAR antagonist ligand or α-RAR agonist ligand as an apoptosis inhibitor C.I.R.D. GALDERMA (FR) 2000-05-16 US claimed
US-5973007-A SURGERY, TRAUMA WOUNDS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1999-10-26 US claimed
EP-0658553-B1 Polycyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof CIRD GALDERMA (FR) 1998-11-04 EP claimed
EP-0740937-A2 Use of retinoids for the manufacture of a pharmaceutical or cosmetic composition CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) 1996-11-06 EP claimed
US-8066976-B2 Foaming compositions for hair care GALDERMA S.A. (CH) 2011-11-29 US disclosed
US-8066975-B2 Psoriasis or seborrheic dermatitis; mixture of clobetasol propionate, an anionic surfactant (sodium lauryl ether sulfate), an amphoteric surfactant ( cocamidopropyl betaines); a propenetrating agent chosen from ethanol, isopropanol, propylene glycol and ethoxydiglycol; foam with good compactnes; shampoo GALDERMA S.A. (CH) 2011-11-29 US disclosed
EP-0658553-B1 Polycyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof CIRD GALDERMA (FR) 1998-11-04 EP disclosed
EP-0740937-A2 Use of retinoids for the manufacture of a pharmaceutical or cosmetic composition CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) 1996-11-06 EP disclosed
EP-0658553-A1 Polycyclic aromatic compounds, pharmaceutical compositions containing them and uses thereof CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) 1995-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234337-A1 FOAMING COMPOSITIONS FOR HAIR CARE RARA, NR5A1, SHH MEN1 2113/4885KMT2A 4554/4885THRB 1456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.